Sodium-free icodextrin and dextrose solution in peritoneal dialysis

Phase 1, open-label, single-arm trial of icodextrin + dextrose in chronic kidney disease (CKD), sponsored by Instituto Mexicano del Seguro Social. Primary endpoints: Number of serious adverse events related to the investigational product at 24 hours and Pain in a scale from 0 to 4 during infusion, dwell, and drain at 24 hours. Status: unknown.